Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-10-09 08:21 3107

Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

SUZHOU, China and ROCKVILLE, Md., Sept. 14, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-09-14 18:35 2207

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-09-07 17:16 2660

Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020

SUZHOU, China and ROCKVILLE, Md., Aug. 27, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-27 18:10 5149

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

SUZHOU, China and ROCKVILLE, Md., Aug. 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-08-18 20:24 3850

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., Aug. 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-08-17 07:30 3203

Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

SUZHOU, China and ROCKVILLE, Md., July 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-22 17:31 2275

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

SUZHOU, China and ROCKVILLE, Md., July 15, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-15 21:07 2263

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-07-06 13:00 2179

Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

SUZHOU, China and ROCKVILLE, Md., June 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-06-22 07:15 3062

Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., June 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-06-18 17:30 2260

Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B

SUZHOU, China, and ROCKVILLE, MD., June 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-06-17 13:20 2610

(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies

SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-05-31 20:00 2363

Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, Md., May 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-05-04 18:30 2115

Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development

SUZHOU, China and ROCKVILLE, MD, March 29, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2020-03-30 08:00 1719

Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2020-03-24 12:30 3657

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2020-03-24 12:24 3815

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2020-03-23 19:00 1671

Ascentage Pharma Announces Clearances for Three Phase Ib/II Clinical Studies of APG-2575 in China and the U.S., Beginning Simultaneous Clinical Development in Three Hematologic Malignancy Indications

SUZHOU, China and ROCKVILLE, MD., March 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-03-09 20:00 2028

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China

SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-02-24 22:00 2445